Tetramethylglycoluril (MEBICAR, Adaptol, Mebicarum) is an anxiolytic similar to organism natural metabolites with nootropic and stress-protective characteristics. Tetramethylglycoluril belongs to a group of non-benzodizepam tranquilizers. It works by effecting on the structure of limbic-reticular activity and 4 main neuromediator systems – γ aminobutyric acid, choline -, serotonin- and adrenergic. Tetramethylglycoluril increases serotonin levels, decreases noradrenaline level with no effect on dopamine and no anticholinergic activity. It acts on hypothalamus emotional zone, thus providing moderate tranquilizing effect. Tetramethylglycoluril improves oxygen consumption by myocardium, normalizes blood electrolyte balance, stimulates protein synthesis and increases cell's energy resource. Tetramethylglycoluril is used to treat neurotic disorders (anxiety, awareness, fear, emotional density, irritability) caused by exhausting psycho-emotional, nervous and physical loads. Mebicar relieves or completely removes nicotine abstinence.

Flunitrazepam is an intermediate-acting benzodiazepine with general properties similar to those of diazepam. It is generally intended to be for short-term treatment for chronic or severe insomniacs who are unresponsive to other hypnotics. The main pharmacological effects of Flunitrazepam are the enhancement of GABA at the GABAA receptor. The physical effects of Flunitrazepam include sedation, muscle relaxation, decreased anxiety, and prevention of convulsions. It causes partial amnesia; individuals are unable to remember certain events that they experience while under the influence of the drug. Chronic use of Flunitrazepam can result in physical dependence and the appearance of a withdrawal syndrome when the drug is discontinued. Flunitrazepam impairs cognitive and psychomotor functions affecting reaction time and driving skill. The use of this drug in combination with alcohol is a particular concern as both central nervous system depressants potentiate each other's toxicity.

Prolintane is an amphetamine-related CNS stimulant and norepinephrine-dopamine reuptake inhibitor that has been used for the treatment of narcolepsy and attention deficit hyperactivity disorder in Africa, Australia, and Europe. Under the trade-name "Katovit", prolintane was commercialized by the Spanish pharmaceutical company, FHER. Katovit was sold until 2001 and was most often used by students and workers as a stimulant to provide energy, promote alertness and concentration. The use of prolintane as a doping agent in athletics has been noted worldwide. Prolintane, like many amphetamine derivatives, increases the concentration of dopamine in the synaptic cleft. Adverse effects of the drug include insomnia, nervousness, irritability, and dizziness. Overdoses of prolintane may cause hallucinations, psychosis, and death. Individuals who abuse prolintane risk becoming dependent as tolerance may develop.

Oxaflozane is non-tricyclic antidepressant with serotoninergic action. In animals, oxaflozane has anti-cataleptic and anti-aggressive action with weak potentiation of stereotypes provoked by amphetamine. Oxaflozane was developed by Solvay Pharma and marketed in France under tradename Conflictan. The drug was discontinued in 2004.

Sulpiride is an atypical antipsychotic drug (although some texts have referred to it as a typical antipsychotic) of the benzamide class used mainly in the treatment of psychosis associated with schizophrenia and major depressive disorder, and sometimes used in low dosage to treat anxiety and mild depression. Sulpiride is commonly used in Europe, Russia and Japan. Sulpiride is a selective antagonist at dopamine D2 and D3 receptors. This action dominates in doses exceeding 600 mg daily. In doses of 600 to 1,600 mg sulpiride shows mild sedating and antipsychotic activity. Its antipsychotic potency compared to chlorpromazine is only 0.2 (1/5). In low doses (in particular 50 to 200 mg daily) its prominent feature is antagonism of presynaptic inhibitory dopamine receptors accounting for some antidepressant activity and a stimulating effect. Therefore, it is in these doses used as a second line antidepressant. Racemic and L-sulpiride significantly decreased stimulated serum gastrin concentration, but they did not affect fasting serum gastrin or basal and stimulated gastric acidity. D-sulpiride significantly decreased gastric acid secretion, without affecting serum gastrin levels.

Emepronium bromide (Cetiprina) is a quarternary ammonium compound with anticholinergic effects. It is mainly used in the treatment of urinary frequency, urge and urge incontinence and is usually administered orally and occasionally intramuscularly. Emepronium bromide was introduced into Britain, after having been used in Sweden for a number of years. The drug was advocated especially for elderly patients suffering from nocturia and urgency with incontinence, when these were due to causes other than obstruction. It was also advocated for enuresis and hypertonic bladder states following surgery or radiotherapy.

Vinylbital is a barbiturate derivative. It was introduced into therapy in 1963 and used as a sedative and in the treatment of insomnia.

Niaprazine is a potent and selective antagonist of 5-HT2A and alpha-1 adrenergic receptors. It was used for the treatment of sleep disturbances in children and was investigated for the treatment of sleep disorders in patients with attention-deficit hyperactivity disorder and autistic disorder.

Bromperidol (marketed as Bromidol, Bromodol) is a butyrophenone derivative. It is a potent and long-acting neuroleptic, used as an antipsychotic in the treatment of schizophrenia. It was discovered at Janssen Pharmaceutica in 1966. Bromperidol is a bromine analog of Haloperidol hydrochloride (sc-203593) which functions as a D2DR (dopamine D2 receptor) antagonist. Studies suggest that cytochrome CYP3A4 catalyzes the dehydration of Bromperidol and N-dealkylation of Bromperidol. In addition, CYP3A4 can oxidize N-dealkylated Bromperidol back into Bromperidol. Alternately, Bromperidol antagonizes the Neuroendocrine DA receptors which regulate hypothalamic LH-RH release.

Nefopam (nefopam hydrochloride) is a potent, rapidly-acting non-narcotic analgesic. It is totally distinct from other centrally-acting analgesics such as morphine, codeine, pentazocine and propoxyphene. Unlike the narcotic agents, nefopam (nefopam hydrochloride) has been shown not to cause respiratory depression. It is indicated for the relief of acute and chronic pain, including post-operative pain, dental pain, musculo-skeletal pain, acute traumatic pain and cancer pain. Its mechanism of action is unclear.